Bioscience Managers' first fund achieves 24.7% IRR
Bioscience Managers revealed that its Australian Bioscience Fund I healthcare fund has returned capital to investors at an annual internal rate of return of 24.7%.
Since its inception in July 2008, the fund called $35 million and ended with $56 million returned, a closing unit price of $1.76 per dollar invested, the fund manager said.
Australian Bioscience I was the first fund run by Bioscience Managers since it was established from the former IB Managers.
It focused on investments in mid-stage healthcare and life science investments, including Alchemia (ASX:ACL), Bionomics (ASX:BNO), Acrux (ASX:ACR) and HeartWare International (ASX:HIN).
The fund’s minimum commitment was $4 million, and investors included Telstra Super, Asia Union Investments, Meat Industry Employees Superannuation Fund and the ANU.
Bioscience Managers Managing Director Jeremy Curnock Cook said the fund has outperformed the S&P/ASX200 Accumulation Index by 68%, “despite the volatility in the past six years and investing in what is regarded as a high-risk sector”.
The company’s second fund, Asia Pacific Healthcare Fund II, will have its final close in September. The fund seeks to raise up to $100 million and has invested in companies including Nexvet Biopharma, Avita Medical (ASX:AVH), AmpliPhi Biosciences and Rex Bionics
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
